New WHO Initiative "Good Pharmacopoeial Practices"
Recommendation

9-11 June 2026
Development, Validation & Control
The WHO started the new initiative "Good Pharmacopoeia Practices" with the goal to harmonise the procedures and the regulations for pharmaceutical standards. It is supposed to support authorities in ensuring the quality of pharmaceutical raw materials and finished products.
The background for the initiative is that the retrospective harmonisation of pharmacopoeia requirements has proven to be difficult. A prospective harmonisation seems to be easier to accomplish. In the end the initiative is supposed to result in the harmonisation of pharmacopoeia standards.
Representatives of all pharmacopoeias are involved in this activity.
The WHO working document comprises an agenda with the planned activities. For instance, in June 2013 it was planned to discuss the feedback that was submitted with regard to the concept paper.
For more detailed information please see the concept paper "Good Pharmacopoeia Practices".
Related GMP News
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation
21.05.2026LCGC Article on Analytical Procedure Lifecycle Approaches


